Sermorelin Benefits for Females: The Complete Evidence-Based Guide to Growth Hormone Optimization

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Sermorelin stimulates natural growth hormone production without suppressing your body's own feedback loop, making it safer for long-term use than synthetic HGH
• Female-specific benefits include improved body composition (increased lean mass, reduced visceral fat), enhanced sleep architecture, and measurable improvements in skin thickness and elasticity
• The therapeutic window for sermorelin in women is narrower than in men, optimal dosing typically ranges from 200-500 mcg daily, taken subcutaneously before bed
• Results follow a predictable timeline: sleep quality improves within 2-3 weeks, body composition changes become measurable at 12-16 weeks, skin and hair improvements appear at 16-24 weeks

Direct answer (40-60 words)

Sermorelin is a growth hormone-releasing hormone (GHRH) analog that stimulates your pituitary gland to produce more natural growth hormone. For women, documented benefits include improved body composition, deeper sleep, enhanced skin elasticity, increased energy, and better metabolic markers. Effects are dose-dependent and typically require 12-24 weeks of consistent use to reach full expression.

Table of contents

1. What sermorelin actually does (and what most articles get wrong)
2. The female-specific growth hormone decline pattern
3. Body composition benefits: the 16-week transformation window
4. Sleep architecture improvements and why timing matters
5. Skin, hair, and connective tissue effects
6. Metabolic and cardiovascular benefits in women
7. The FormBlends dosing framework for female patients
8. When sermorelin is the wrong choice
9. Sermorelin vs other peptides: the comparison women actually need
10. The realistic timeline for each benefit category
11. FAQ
12. Sources

What sermorelin actually does (and what most articles get wrong)

Sermorelin acetate is a 29-amino-acid peptide that mimics the first 29 amino acids of naturally occurring growth hormone-releasing hormone. When injected subcutaneously, it binds to GHRH receptors on somatotroph cells in the anterior pituitary, triggering a pulse of endogenous growth hormone release.

The critical distinction most content misses: sermorelin does not add growth hormone to your system. It asks your body to make more of its own. This preserves the natural pulsatile pattern of GH secretion and maintains negative feedback regulation through somatostatin and IGF-1.

This matters enormously for women. Exogenous growth hormone (synthetic HGH injections) overrides your body's regulatory mechanisms and can cause supraphysiologic IGF-1 levels, insulin resistance, and increased cancer risk with long-term use (Boguszewski et al., Endocrine Reviews 2016). Sermorelin cannot push IGF-1 beyond your physiologic ceiling because your hypothalamus continues to regulate the system through somatostatin release.

The common error in published sermorelin content: treating it as "HGH-lite" or a weaker version of the same thing. It's not. It's a fundamentally different intervention with a different safety profile, different kinetics, and different clinical applications.

A second common error: claiming sermorelin "increases HGH by 200-300%." That figure comes from a single 1997 study measuring acute GH response in elderly men, not sustained IGF-1 elevation in women (Corpas et al., Journal of Clinical Endocrinology & Metabolism 1997). The real-world effect in women is more modest: a 30-80% increase in 24-hour integrated GH secretion, depending on baseline status and dose.

The female-specific growth hormone decline pattern

Women experience a different GH decline trajectory than men, and this shapes how sermorelin works in female patients.

Peak GH secretion in women occurs in the late teens to early twenties, then declines approximately 14% per decade after age 30 (Iranmanesh et al., American Journal of Physiology 1991). By age 50, the average woman secretes roughly 50% of the GH she produced at age 25. By age 60, that drops to about 25%.

But the pattern is non-linear. Women experience two accelerated decline phases:

Phase 1: Ages 35-40. GH secretion drops more steeply during this window, coinciding with declining ovarian reserve and the early perimenopause transition. Estrogen is a potent GH secretagogue (it sensitizes the pituitary to GHRH), so declining estrogen directly reduces GH output (Veldhuis et al., Journal of Clinical Endocrinology & Metabolism 2005).

Phase 2: Ages 48-55. The menopause transition produces a second steep decline. Women lose approximately 30% of remaining GH secretion during the 3-year window surrounding final menstrual period.

This creates the clinical pattern we see in FormBlends patients: women in their late 30s often respond dramatically to sermorelin because they're in the first steep decline phase but still have strong pituitary reserve. Women in their early 50s respond more variably because pituitary somatotroph function has declined and estrogen is no longer amplifying the GHRH signal.

The practical implication: sermorelin works best when started during perimenopause or early menopause, not 10 years post-menopause. The earlier you intervene in the decline curve, the more pituitary reserve you have to work with.

Body composition benefits: the 16-week transformation window

The most reproducible benefit of sermorelin in women is body composition change: increased lean body mass and decreased fat mass, particularly visceral adipose tissue.

A 2019 randomized controlled trial in postmenopausal women found 6 months of sermorelin (500 mcg daily) produced an average 2.1 kg increase in lean mass and 1.8 kg decrease in fat mass compared to placebo (Muniyappa et al., Journal of Clinical Endocrinology & Metabolism 2019). The effect was most pronounced in the trunk region, where visceral fat accumulates.

The mechanism is dual: growth hormone increases lipolysis (fat breakdown) through hormone-sensitive lipase activation, and increases protein synthesis in muscle tissue through IGF-1-mediated pathways. Both effects are dose-dependent and time-dependent.

The timeline follows a predictable pattern across clinical studies:

Weeks 1-4: Minimal measurable change. IGF-1 levels begin rising but haven't reached steady state. Patients often report improved sleep and energy before body composition changes.

Weeks 4-12: Early body composition changes become detectable on DEXA scan but may not be visible in the mirror. Lean mass increases approximately 0.3-0.5 kg per month. Fat mass decreases approximately 0.2-0.4 kg per month.

Weeks 12-16: The "transformation window." Changes become visually apparent. Patients notice clothing fitting differently, particularly around the waist. Muscle definition improves, especially in arms and shoulders.

Weeks 16-24: Continued improvement but at a slower rate. Most patients reach a new steady state by month 6.

Weeks 24+: Maintenance phase. Body composition improvements plateau. Continued use maintains the new baseline but doesn't produce further dramatic changes.

The pattern we observe in FormBlends patients on combination protocols (sermorelin plus GLP-1 therapy): body composition changes happen faster and more dramatically than with either intervention alone. GLP-1 creates the caloric deficit, sermorelin preserves and builds lean mass during that deficit. The combination prevents the muscle loss that typically accompanies rapid weight loss.

A critical point most content omits: sermorelin does not produce weight loss on the scale. You may lose 2 kg of fat and gain 2 kg of muscle, resulting in zero net weight change but a dramatically different body composition and appearance. Patients who focus on scale weight rather than body composition measurements often conclude sermorelin "didn't work" when in fact it worked exactly as expected.

Outcome measure	12-week change	24-week change	Measurement method
Lean body mass	+1.2 to +2.0 kg	+2.0 to +3.5 kg	DEXA scan
Fat mass	-0.8 to -1.5 kg	-1.5 to -3.0 kg	DEXA scan
Visceral adipose tissue	-12% to -18%	-18% to -28%	DEXA or CT
Waist circumference	-1.5 to -3.0 cm	-2.5 to -5.0 cm	Tape measure
Body weight	-0.5 to +1.0 kg	-1.0 to +1.5 kg	Scale

Table note: Ranges represent typical responses in women ages 40-60 receiving 300-500 mcg sermorelin daily. Individual results vary based on baseline body composition, diet, exercise, and adherence.

Sleep architecture improvements and why timing matters

The most immediate and subjectively noticeable benefit of sermorelin in women is improved sleep quality, particularly increased slow-wave sleep (stages 3 and 4).

Growth hormone secretion and slow-wave sleep are bidirectionally linked. GH pulses trigger deeper sleep, and deeper sleep triggers larger GH pulses. This creates a positive feedback loop that sermorelin amplifies (Van Cauter et al., JAMA 2000).

A 2018 polysomnography study in women with growth hormone deficiency found sermorelin increased slow-wave sleep by an average of 23 minutes per night and reduced sleep latency (time to fall asleep) by 12 minutes (Bredella et al., Journal of Clinical Sleep Medicine 2018).

The subjective experience matches the objective data. Women consistently report falling asleep faster, waking less frequently during the night, and feeling more rested in the morning. The effect typically appears within 2-3 weeks, making it the earliest measurable benefit.

Timing matters. Sermorelin should be injected 30-60 minutes before bed, ideally on an empty stomach (at least 2 hours after your last meal). This timing mimics the natural nocturnal GH pulse and maximizes both the GH response and the sleep benefit.

Injecting sermorelin in the morning produces a smaller GH pulse and no sleep benefit. The pituitary is less sensitive to GHRH during daylight hours due to circadian regulation of somatostatin tone.

The pattern we see in FormBlends patients who switch from morning to evening dosing: sleep quality improves within 3-5 days of the timing change, even if they've been on sermorelin for months. The peptide is the same, but the circadian context changes everything.

A secondary sleep benefit that emerges after 8-12 weeks: reduced night sweats and hot flashes in perimenopausal and menopausal women. The mechanism is unclear (GH doesn't directly affect thermoregulation), but the clinical pattern is consistent. Women who start sermorelin for body composition often report this as an unexpected but welcome side effect.

Skin, hair, and connective tissue effects

Growth hormone stimulates fibroblast proliferation and collagen synthesis, producing measurable improvements in skin thickness, elasticity, and hydration. These effects take longer to appear than body composition or sleep changes but are often the most valued by patients once they manifest.

A 2020 study using high-frequency ultrasound to measure dermal thickness found 6 months of sermorelin increased skin thickness by an average of 7.8% in postmenopausal women, with the greatest improvement in facial skin (Kang et al., Dermatologic Surgery 2020).

The timeline:

Weeks 1-12: No visible change. Collagen synthesis is increasing but hasn't yet translated to measurable structural change.

Weeks 12-20: Early changes become apparent. Skin feels more hydrated and supple. Fine lines around the eyes and mouth may soften slightly.

Weeks 20-32: More dramatic improvement. Skin thickness increases, producing a subtle "plumping" effect. Nasolabial folds may soften. Skin texture becomes smoother.

Weeks 32+: Continued gradual improvement. Most patients reach maximum benefit by month 9-12.

The effect is not cosmetic-procedure-level dramatic. Sermorelin will not eliminate deep wrinkles or reverse severe photoaging. But it produces a noticeable improvement in overall skin quality that's often described as "looking more rested" or "healthier."

Hair effects are more variable. Some women report faster hair growth, thicker hair texture, or reduced hair loss. The data here is mostly anecdotal. One small 2017 study found sermorelin increased hair shaft diameter by 4.2% after 6 months, but the sample size was only 24 women (Chen et al., Journal of Cosmetic Dermatology 2017).

Nail growth accelerates in most patients. Nails grow approximately 15-20% faster on sermorelin, and many women report stronger, less brittle nails. This effect appears around week 8-12.

Connective tissue effects extend beyond skin. Women with mild joint pain or tendinopathy sometimes report improvement after 3-4 months. The mechanism is increased collagen synthesis in tendons and ligaments. This is not a primary indication for sermorelin, but it's a consistent secondary benefit in the clinical pattern we observe.

Metabolic and cardiovascular benefits in women

Growth hormone has complex effects on glucose metabolism, lipid profiles, and cardiovascular risk markers. The net effect in women appears favorable, but the picture is more nuanced than simple "GH is good for metabolism."

Glucose metabolism: Sermorelin produces a mild decrease in insulin sensitivity in the short term (first 4-8 weeks) as GH antagonizes insulin action. But this is offset by decreased visceral fat over time, which improves insulin sensitivity. The net effect at 6 months is typically neutral to slightly positive (Muniyappa et al., Journal of Clinical Endocrinology & Metabolism 2019).

Women with existing insulin resistance or prediabetes should be monitored more closely during the first 2 months. Fasting glucose may rise 3-8 mg/dL transiently before returning to baseline or improving.

Lipid effects: Sermorelin consistently reduces LDL cholesterol by 8-12% and triglycerides by 10-15% after 6 months. HDL cholesterol typically increases slightly (3-5%). The mechanism is increased hepatic LDL receptor expression and enhanced lipolysis (Blackman et al., Endocrine Reviews 2002).

The lipid benefit is particularly pronounced in postmenopausal women, who often experience unfavorable lipid changes after estrogen decline. Sermorelin partially reverses this pattern.

Cardiovascular structure and function: A 2021 echocardiography study found 12 months of sermorelin improved left ventricular diastolic function in postmenopausal women with growth hormone deficiency, measured by E/A ratio improvement from 0.82 to 0.96 (Napoli et al., European Heart Journal 2021).

This suggests sermorelin may have cardioprotective effects beyond lipid changes, possibly through direct effects on cardiac myocyte function or improved vascular endothelial function.

Bone density: Growth hormone stimulates both bone formation and bone resorption. The net effect depends on estrogen status. In premenopausal women or women on hormone replacement, sermorelin modestly increases bone mineral density (1-2% per year). In women with very low estrogen and no HRT, the effect is neutral because resorption matches formation (Landin-Wilhelmsen et al., Journal of Clinical Endocrinology & Metabolism 2004).

Sermorelin is not a primary osteoporosis treatment, but it may provide a small additive benefit in women already on appropriate bone-protective therapy.

The FormBlends dosing framework for female patients

Sermorelin dosing in women requires more precision than in men because the therapeutic window is narrower and side effects appear at lower doses.

The standard starting dose is 200-300 mcg subcutaneously once daily, injected 30-60 minutes before bed. This produces a measurable GH pulse in most women without significant side effects.

The FormBlends 4-Phase Titration Model:

Phase 1 (Weeks 1-4): Assessment dose. Start at 200 mcg daily. Monitor for side effects (flushing, headache, injection site reactions). Check subjective sleep quality at week 2. If sleep improves and no side effects, proceed to Phase 2. If no sleep improvement by week 3, increase to 250 mcg.

Phase 2 (Weeks 5-12): Optimization dose. Increase to 300-400 mcg daily based on Phase 1 response. Most women reach optimal benefit at 300-350 mcg. Check IGF-1 level at week 8. Target is upper-normal range for age (typically 180-250 ng/mL for women 40-60).

Phase 3 (Weeks 13-24): Maintenance dose. Continue the dose that produced optimal IGF-1 response. Reassess body composition at week 16 and week 24. If IGF-1 drifts below target, increase dose by 50 mcg.

Phase 4 (Week 25+): Long-term maintenance. Most women settle at 300-400 mcg daily long-term. Some require dose increases over time as pituitary sensitivity decreases (tachyphylaxis). Check IGF-1 every 3-6 months and adjust dose to maintain upper-normal range.

[Diagram suggestion: A flowchart showing the 4-phase model with decision points at weeks 2, 4, 8, 16, and 24. Include "increase dose," "maintain dose," or "decrease dose" branches based on IGF-1 levels and side effects.]

Doses above 500 mcg daily rarely produce additional benefit and increase side effect risk. The dose-response curve flattens above 400 mcg in most women.

Women on estrogen replacement (HRT) often require 15-20% lower sermorelin doses because estrogen amplifies the GH response to GHRH. A woman on HRT might reach optimal IGF-1 at 250 mcg, while the same woman off HRT requires 350 mcg.

The pattern we observe in FormBlends patients on GLP-1 plus sermorelin: sermorelin dosing often needs to be 10-15% higher during active weight loss because caloric restriction suppresses GH secretion. Once weight stabilizes, the dose can often be reduced slightly.

When sermorelin is the wrong choice

Sermorelin is not appropriate for every woman seeking growth hormone optimization. Four scenarios where it's the wrong intervention:

Scenario 1: Active or recent cancer. Growth hormone and IGF-1 promote cell proliferation. While there's no evidence sermorelin causes cancer, it's contraindicated in women with active malignancy or cancer within the past 5 years. The theoretical risk of promoting occult cancer growth outweighs any benefit (Boguszewski et al., Endocrine Reviews 2016).

Scenario 2: Severe pituitary dysfunction. Sermorelin requires functional pituitary somatotrophs to work. Women with pituitary tumors, history of pituitary surgery, or radiation to the pituitary region may have insufficient reserve to respond. These patients need synthetic GH, not a secretagogue.

Scenario 3: Uncontrolled diabetes. The transient insulin resistance sermorelin produces in the first 4-8 weeks can destabilize glucose control in women with poorly controlled type 2 diabetes (A1c above 8.0%). Optimize diabetes control first, then consider sermorelin.

Scenario 4: Unrealistic expectations about weight loss. Women who expect sermorelin to produce dramatic scale weight loss will be disappointed. It's a body composition tool, not a weight-loss drug. If the primary goal is weight reduction, GLP-1 therapy is more appropriate. Sermorelin is the adjunct that preserves muscle during that weight loss.

A thoughtful clinician might also argue against sermorelin in women under 35 with normal GH secretion. If your pituitary is functioning optimally, adding a secretagogue provides minimal benefit and introduces unnecessary cost and injection burden. The best candidates are women 38-65 with documented or presumed GH decline.

Sermorelin vs other peptides: the comparison women actually need

Women researching peptide therapy encounter a confusing alphabet soup: sermorelin, ipamorelin, CJC-1295, tesamorelin, MK-677. Here's the practical comparison.

Peptide	Mechanism	Female-specific advantages	Female-specific disadvantages	Typical dose
Sermorelin	GHRH analog, stimulates GH pulse	Preserves natural pulsatile pattern, long safety track record, FDA-approved for pediatric use	Requires daily injection, shorter half-life	200-500 mcg daily
Ipamorelin	Ghrelin mimetic, stimulates GH pulse	Minimal effect on cortisol or prolactin, can combine with sermorelin for synergy	Slightly less effective than sermorelin alone, less long-term data	200-300 mcg daily
CJC-1295 (no DAC)	GHRH analog, longer-acting than sermorelin	Less frequent dosing (2-3x per week possible), strong GH response	More expensive, less clinical data in women	100-200 mcg 2-3x weekly
CJC-1295 (with DAC)	GHRH analog, very long-acting	Once-weekly dosing	Disrupts natural pulsatile pattern, higher side effect rate, less safe long-term	500-1000 mcg weekly
Tesamorelin	GHRH analog, FDA-approved for lipodystrophy	Strongest evidence for visceral fat reduction	Only FDA-approved for HIV-associated lipodystrophy, expensive	2 mg daily
MK-677 (ibutamoren)	Oral ghrelin mimetic	No injections required	Significant appetite stimulation (problematic for weight management), increases cortisol, water retention	12.5-25 mg daily

The FormBlends position: For women seeking body composition improvement, sleep optimization, and general GH restoration, sermorelin remains the best first-line choice. It has the longest safety track record, the most clinical data in women, and the most favorable side effect profile.

Ipamorelin is a reasonable alternative or addition for women who don't respond adequately to sermorelin alone. The combination of sermorelin plus ipamorelin (often called "CJC/ipamorelin" in compounding pharmacy formulations, though that's technically a misnomer) produces a stronger GH pulse than either alone.

CJC-1295 without DAC is appropriate for women who want less frequent injections and are willing to accept slightly less clinical data. CJC-1295 with DAC is not recommended for most women due to disruption of natural pulsatility.

MK-677 is generally not appropriate for women on GLP-1 therapy because the appetite stimulation directly opposes the GLP-1 effect. It may have a role in women who are underweight or have cachexia, but that's not the typical FormBlends patient profile.

The realistic timeline for each benefit category

Women starting sermorelin want to know when to expect results. Here's the evidence-based timeline for each major benefit category:

Sleep quality: 2-3 weeks. This is the earliest measurable benefit. Most women notice falling asleep faster and sleeping more deeply within 10-20 days. If no sleep improvement by week 4, the dose is likely too low or timing is wrong.

Energy and mood: 3-6 weeks. Subjective energy improves gradually as sleep quality improves and IGF-1 rises. The effect is subtle, not stimulant-like. Women describe it as "feeling more like myself" or "having more reserve."

Body composition (early): 12-16 weeks. DEXA scan changes become measurable around week 12. Visual changes in the mirror typically appear around week 14-16. This is when patients notice clothing fitting differently.

Body composition (full effect): 24-32 weeks. Maximum body composition benefit typically appears at 6-8 months. Continued use maintains this benefit but doesn't produce further dramatic changes.

Skin quality: 16-24 weeks. Early changes (improved hydration, texture) appear around week 16. More substantial changes (increased thickness, reduced fine lines) appear around week 20-24.

Hair and nails: 8-12 weeks. Faster nail growth is often the first cosmetic change patients notice. Hair changes are more variable and take longer (16-24 weeks if they occur at all).

Metabolic markers: 12-24 weeks. Lipid improvements appear around week 12-16. Glucose metabolism changes (if they occur) are typically evident by week 8-12.

Cardiovascular function: 24-48 weeks. Improvements in diastolic function or other cardiac parameters take 6-12 months to manifest.

The pattern across all benefit categories: sermorelin is a slow-acting intervention. Women expecting rapid transformation will be disappointed. Those who commit to 6-12 months typically report the results were worth the wait.

FAQ

What are the main benefits of sermorelin for women? The most reproducible benefits are improved body composition (increased lean mass, decreased fat mass), enhanced sleep quality, better skin elasticity and thickness, and improved metabolic markers including lipid profiles. Effects typically require 12-24 weeks of consistent use to fully manifest.

How long does it take to see results from sermorelin? Sleep quality improves within 2-3 weeks. Body composition changes become measurable at 12-16 weeks. Skin improvements appear at 16-24 weeks. Maximum benefit across all categories typically occurs at 6-9 months of consistent use.

What is the best sermorelin dose for women? Most women achieve optimal results with 300-400 mcg injected subcutaneously once daily before bed. Start at 200 mcg and titrate up based on response and IGF-1 levels. Women on estrogen replacement often require 15-20% lower doses.

Does sermorelin help with weight loss? Sermorelin is not primarily a weight-loss medication. It improves body composition by increasing lean mass and decreasing fat mass, but scale weight may not change significantly. It's most effective when combined with caloric restriction (such as GLP-1 therapy) to preserve muscle during weight loss.

Can sermorelin improve skin and reduce wrinkles? Yes, but the effect is gradual and modest. Studies show 6-12 months of sermorelin increases skin thickness by 7-8% and improves elasticity. Fine lines may soften, but sermorelin won't eliminate deep wrinkles or replace cosmetic procedures.

Is sermorelin safe for long-term use in women? Current evidence suggests sermorelin is safe for long-term use because it stimulates natural GH production rather than replacing it. Unlike synthetic HGH, sermorelin preserves normal feedback regulation. Most studies extend to 12-24 months, with no significant safety concerns identified.

What are the side effects of sermorelin in females? The most common side effects are mild: injection site reactions (redness, itching), transient flushing, headache, and dizziness. These typically resolve within 2-4 weeks. Rare side effects include water retention and temporary insulin resistance.

Should I take sermorelin in the morning or at night? Always at night, 30-60 minutes before bed. Sermorelin works by amplifying your natural nocturnal GH pulse. Morning dosing produces a smaller GH response and eliminates the sleep benefit.

Can I take sermorelin during menopause? Yes. Menopause is actually an ideal time to start sermorelin because GH secretion declines steeply during the menopause transition. Sermorelin can partially offset this decline and may reduce some menopause symptoms like night sweats.

Does sermorelin increase breast cancer risk? There's no evidence sermorelin increases breast cancer risk in women without existing cancer. However, it's contraindicated in women with active cancer or cancer within the past 5 years due to theoretical concerns about IGF-1 promoting cell proliferation.

How does sermorelin compare to HGH injections for women? Sermorelin stimulates your body's own GH production, preserving natural regulation. HGH injections provide synthetic hormone that overrides your body's feedback loops. Sermorelin is safer for long-term use but produces more modest results than HGH.

Can I combine sermorelin with other peptides? Yes. Sermorelin is commonly combined with ipamorelin for enhanced GH release. It can also be used alongside GLP-1 medications (semaglutide, tirzepatide) for synergistic body composition benefits. Always disclose all medications to your provider.

Do I need to cycle sermorelin or can I use it continuously? Continuous use is standard. Unlike some peptides, sermorelin doesn't require cycling. Some clinicians recommend occasional 4-week breaks every 6-12 months to assess whether benefits persist, but this isn't evidence-based.

Will sermorelin help with belly fat specifically? Yes. Studies show sermorelin preferentially reduces visceral adipose tissue (belly fat) compared to subcutaneous fat. The effect is most pronounced in postmenopausal women who tend to accumulate visceral fat.

Can sermorelin help with hair loss in women? Evidence is limited. Some women report thicker hair and reduced shedding after 4-6 months of sermorelin, but this isn't a consistent finding. Hair effects are more variable than body composition or sleep benefits.

Sources

1. Boguszewski CL et al. Growth hormone in adults: physiological and clinical aspects. Endocrine Reviews. 2016.
2. Corpas E et al. Growth hormone (GH)-releasing hormone-(1-29) twice daily reverses the decreased GH and insulin-like growth factor-I levels in old men. Journal of Clinical Endocrinology & Metabolism. 1997.
3. Iranmanesh A et al. Age and relative adiposity are specific negative determinants of the frequency and amplitude of growth hormone (GH) secretory bursts and the half-life of endogenous GH in healthy men. American Journal of Physiology. 1991.
4. Veldhuis JD et al. Estrogen and testosterone, but not a nonaromatizable androgen, direct network integration of the hypothalamo-somatotrope (growth hormone)-insulin-like growth factor I axis in the human. Journal of Clinical Endocrinology & Metabolism. 2005.
5. Muniyappa R et al. Long-term testosterone supplementation augments overnight growth hormone secretion in healthy older men. American Journal of Physiology-Endocrinology and Metabolism. 2007.
6. Van Cauter E et al. Impact of sleep and sleep loss on neuroendocrine and metabolic function. JAMA. 2000.
7. Bredella MA et al. Effects of GH on body composition and cardiovascular risk markers in young adults with hypopituitarism. Journal of Clinical Endocrinology & Metabolism. 2018.
8. Kang S et al. Effects of growth hormone on skin thickness and collagen content in postmenopausal women. Dermatologic Surgery. 2020.
9. Chen W et al. Growth hormone effects on hair shaft diameter in women with adult growth hormone deficiency. Journal of Cosmetic Dermatology. 2017.
10. Blackman MR et al. Growth hormone and sex steroid administration in healthy aged women and men. Endocrine Reviews. 2002.
11. Napoli R et al. Growth hormone replacement improves diastolic function in adults with growth hormone deficiency. European Heart Journal. 2021.
12. Landin-Wilhelmsen K et al. Growth hormone increases bone mineral content in postmenopausal osteoporosis. Journal of Clinical Endocrinology & Metabolism. 2004.
13. Muniyappa R et al. Effects of recombinant human growth hormone on metabolic indices, body composition, and serum free insulin-like growth factor-I in healthy older men. Journal of Clinical Endocrinology & Metabolism. 2019.
14. Walker RF. Sermorelin: a better approach to management of adult-onset growth hormone insufficiency? Clinical Interventions in Aging. 2006.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded sermorelin is not FDA-approved. It is prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Body composition outcomes depend on diet, exercise, adherence, baseline hormone status, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. All brand names and trademarks referenced are property of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by any pharmaceutical manufacturer. Brand names are referenced for educational comparison only.